| Issue Date |
Title |
Author(s) |
| 2012 |
Clinical pathway for surgical treatment of primary lung cancer (2012 Edition) |
Zhi, Xiu-Yi;He, Jian-Xing;Li, Hui;Zhang, Xun;Jiang, Ge-Ning;Zhao, Heng;Liu, Lun-Xu;Liu, De-Ruo;Li, Shan-Qing;Li, Jian;Zhou, Qing-Hua;Wang, Qun;Wang, Ru-Wen;Fu, Jian-Hua;Xu, Lin;Zhang, Lin-You;Zhou, Nai-Kang;Xu, Shao-Fa |
| Mar-2021 |
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer |
Ni, Jun;Huang, Miao;Zhang, Li;Wu, Nan;Bai, Chun-Xue;Chen, Liang-An;Liang, Jun;Liu, Qian;Wang, Jie;Wu, Yi-Long;Zhang, Feng-Chun;Zhang, Shu-Yang;Chen, Chun;Chen, Jun;Fang, Wen-Tao;Gao, Shu-Geng;Hu, Jian;Jiang, Tao;Li, Shan-Qing;Li, He-Cheng;Liao, Yong-De;Liu, Yang;Liu, De-Ruo;Liu, Hong-Xu;Liu, Jian-Yang;Liu, Lun-Xu;Wang, Meng-Zhao;Wang, Chang-Li;Yang, Fan;Yang, Yue;Zhang, Lan-Jun;Zhi, Xiu-Yi;Zhong, Wen-Zhao;Guan, Yu-Zhou;Guo, Xiao-Xiao;He, Chun-Xia;Li, Shao-Lei;Li, Yue;Liang, Nai-Xin;Lu, Fang-Liang;Lv, Chao;Lv, Wei;Si, Xiao-Yan;Tan, Feng-Wei;Wang, Han-Ping;Wang, Jiang-Shan;Yan, Shi;Yang, Hua-Xia;Zhu, Hui-Juan;Zhuang, Jun-Ling;Zhuo, Ming-Lei |
| 2018 |
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study |
Zhong, Wen-Zhao;Wang, Qun;Mao, Wei-Min;Xu, Song-Tao;Wu, Lin;Shen, Yi;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Xu, Lin;Wang, Jun;Fei, Ke;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yan, Hong-Hong;Yang, Xue-Ning;Zhou, Qing;Wu, Yi-Long |
| 1-Mar-2021 |
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial |
Zhong, Wen-Zhao;Wang, Qun;Mao, Wei-Min;Xu, Song-Tao;Wu, Lin;Wei, Yu-Cheng;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Yin, Rong;Yang, Fan;Ren, Sheng-Xiang;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yang, Jin-Ji;Yan, Hong-Hong;Yang, Xue-Ning;Liu, Si-Yang;Zhou, Qing;Wu, Yi-Long |
| 8-Nov-2021 |
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes |
Liu, Si-Yang;Bao, Hua;Wang, Qun;Mao, Wei-Min;Chen, Yedan;Tong, Xiaoling;Xu, Song-Tao;Wu, Lin;Wei, Yu-Cheng;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Yin, Rong;Yang, Fan;Ren, Sheng-Xiang;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yan, Hong-Hong;Dong, Song;Zhang, Xu-Chao;Su, Jian;Yang, Jin-Ji;Yang, Xue-Ning;Zhou, Qing;Wu, Xue;Shao, Yang;Zhong, Wen-Zhao;Wu, Yi-Long |
| 2013 |
A NON-INTERVENTIONAL STUDY ON EGFR MUTATION STATUS AND CLINICAL OUTCOMES OF CHINESE PATIENTS WITH COMPLETELY RESECTED LUNG ADENOCARCINOMA (ICAN STUDY) |
Wu, Yi-Long;Wang, Jun;Chu, Xiang-Yang;Liu, Zhi-Dong;Shen, Yi;Ma, Haitao;Fu, Xiang-Ning;Hu, Jian;Zhou, Nai-Kang;Liu, Yongyu;Zhou, Xinming;Wang, Jian-Jun;Yang, Kang;Li, Jian;Xu, Lin;Wang, Si-Yu;Wang, Qun;Liu, Lun-Xu;Xu, Shun;Li, Shanqing;Chen, Zhongyuan;Luo, Honghe;Chen, Ying;Wang, Changli |
| 2013 |
A prospective comparison study on EGFR mutations by direct sequencing and ARMS in completely resected Chinese non-small cell lung cancer with adenocarcinoma histology (ICAN) |
Zhang, Xuchao;Wu, Yi Long;Wang, Jun;Chu, Xiang-Yang;Liu, Zhi-Dong;Shen, Yi;Ma, Haitao;Fu, Xiang-Ning;Hu, Jian;Zhou, Nai-Kang;Liu, Yongyu;Zhou, Xinming;Wang, Jian-Jun;Yang, Kang;Xu, Lin;Li, Jian;Wang, Si-Yu;Wang, Qun;Liu, Lun-Xu;Xu, Shun |
| Dec-2020 |
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study |
Zeng, Jian;Mao, Wei-Min;Chen, Qi-Xun;Luo, Tao-Bo;Wu, Yi-Long;Zhou, Qing;Yang, Xue-Ning;Yan, Hong-Hong;Zhong, Wen-Zhao;Wang, Qun;Xu, Song-Tao;Wu, Lin;Shen, Yi;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Xu, Lin;Wang, Jun;Fei, Ke;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao |
| 2019 |
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104) |
Xu, Song-Tao;Xi, Jun-Jie;Zhong, Wen-Zhao;Mao, Wei-Min;Wu, Lin;Shen, Yi;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Xu, Lin;Wang, Jun;Fei, Ke;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yan, Hong-Hong;Yang, Xue-Ning;Zhang, Yong-Xing;Yin, Jia-Cheng;Wang, Qun;Wu, Yi-Long |
